Arcus Biosciences stock (US75626R1077): clinical update on TIGIT and anti-CD39 keeps focus on cancer pipeline

Arcus Biosciences has reported fresh clinical data and regulatory updates around its TIGIT and anti-CD39 programs in lung and gastrointestinal cancer, drawing investor attention to the biotech’s immuno-oncology pipeline and cash position.

Arcus Biosciences has recently highlighted new clinical data and regulatory progress for key immuno-oncology candidates targeting TIGIT and CD39, including the combinations domvanalimab plus zimberelimab and quemliclustat-based regimens in lung and gastrointestinal cancers, according to company updates and conference presentations reported in April and May 2025 by Arcus Biosciences and major oncology meetings such as AACR and ASCO.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Arcus Biosciences
• Sector/industry: Biotechnology, immuno-oncology
• Headquarters/country: Hayward, California, United States
• Core markets: Oncology therapies for global markets, with a strong focus on the US
• Key revenue drivers: Collaboration payments and potential future product sales from cancer immunotherapies
• Home exchange/listing venue: New York Stock Exchange (ticker: RCUS)
• Trading currency: US dollar (USD)

Arcus Biosciences: core business model

Arcus Biosciences is a clinical-stage biotechnology company focused on developing cancer immunotherapies, particularly antibody and small-molecule programs designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Its strategy centers on targeting pathways such as TIGIT, PD-1 and CD39 to improve the efficacy of existing checkpoint inhibitors.

The company’s pipeline features several advanced assets, including the anti-TIGIT antibody domvanalimab and the anti-CD39 antibody quemliclustat, often evaluated in combination with Arcus’s own PD-1 antibody zimberelimab or with partners’ therapies. Many of these clinical programs are pursued in collaboration with Gilead Sciences, which has entered into a broad strategic partnership to co-develop and co-commercialize selected Arcus candidates, according to the companies’ collaboration agreements as reported by Arcus and Gilead on 07/31/2020 and in subsequent updates.

In the collaboration structure, Gilead typically provides a significant share of funding for global development while Arcus contributes scientific leadership, early clinical development expertise and certain US commercialization activities. Milestone and opt-in payments have historically represented an important source of cash for Arcus, supplementing equity financing typical for clinical-stage biotechs.

Main revenue and product drivers for Arcus Biosciences

As a company without an approved product on the market, Arcus Biosciences currently generates revenue primarily from collaboration and license agreements, notably with Gilead Sciences. These revenues relate to upfront payments, development milestones and cost sharing for ongoing trials and are closely tied to the progress and scope of the joint pipeline programs, according to Arcus’s quarterly and annual reports, such as the Form 10-K published on 02/28/2025 for the full year 2024.

The most advanced potential product driver is domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody designed to reduce effector function–related toxicities while maintaining checkpoint inhibition. Domvanalimab is being evaluated in combinations including domvanalimab plus zimberelimab for first-line metastatic non–small cell lung cancer (NSCLC), where Arcus has reported encouraging progression-free survival and response rate data in Phase 2 and ongoing Phase 3 studies, including updates shared at the ASCO Annual Meeting in June 2024, according to conference materials and Arcus press communications as of 06/03/2024.

Quemliclustat, an anti-CD39 monoclonal antibody, represents another key pillar of Arcus’s strategy. CD39 is involved in the adenosine pathway that can suppress immune responses within the tumor microenvironment. By blocking CD39, quemliclustat aims to enhance anti-tumor immunity and potentially improve outcomes when combined with chemotherapy and other immunotherapies. Early and mid-stage data in pancreatic and other gastrointestinal cancers have been presented at major oncology meetings, with additional readouts anticipated over the next years, based on Arcus’s clinical pipeline disclosures and updates presented at conferences such as AACR 2024 and 2025.

Beyond these core assets, Arcus also develops small-molecule inhibitors targeting the adenosine A2a and A2b receptors as well as other immuno-modulatory pathways. While these programs are earlier-stage, they broaden the potential addressable market across tumor types and may provide combination options that differentiate Arcus’s portfolio in a crowded immuno-oncology landscape.

Recent clinical and regulatory milestones

In the last 12 to 18 months, Arcus Biosciences has reported several notable clinical and regulatory updates that frame current investor discussion. Among them, the company shared additional data from the domvanalimab plus zimberelimab program in first-line metastatic NSCLC, including extended follow-up results that suggested durable responses and progression-free survival trends compared with historical benchmarks, according to data presented at the ASCO Annual Meeting 2024 and summarized by Arcus in a company press release dated 06/03/2024.

In gastrointestinal cancers, Arcus has advanced combination regimens involving quemliclustat and chemotherapy. Updated Phase 1b/2 data in pancreatic cancer and other GI tumor types were discussed at oncology conferences in late 2024 and early 2025, showing tolerability profiles considered manageable and signals of anti-tumor activity that justified continued development, based on presentations and Arcus’s public commentary around AACR 2025 and ASCO GI 2025.

On the regulatory front, the domvanalimab and zimberelimab combination has moved into pivotal-stage development in NSCLC through ongoing global Phase 3 trials conducted under the Gilead partnership. These trials are designed to support potential future regulatory submissions in the United States and other major markets if efficacy and safety endpoints are met. The step from Phase 2 to Phase 3 has been one of the key milestones signaling that Arcus’s TIGIT strategy could translate into a late-stage asset with commercial potential, as highlighted in Arcus and Gilead joint updates as of 11/09/2023 and subsequent clinical progress announcements.

Investors also monitor regulatory interactions and the broader environment for TIGIT-directed therapies. Over the past few years, large pharmaceutical companies have advanced their own TIGIT programs, with mixed results across indications. This creates both competitive pressure and validation for the target class. Arcus’s ability to design differentiated trial populations, dosing regimens and combination partners is seen as a critical factor for the eventual positioning of domvanalimab in real-world oncology practice.

Financial position and cash runway considerations

For a clinical-stage biotech, cash management and runway are crucial elements of the investment case. Arcus Biosciences reported cash, cash equivalents and marketable securities sufficient to fund planned operations for multiple years based on current development plans, according to its Form 10-K for 2024 filed on 02/28/2025 and subsequent first-quarter 2025 results discussed in May 2025. The company’s collaboration with Gilead provides cost sharing on major programs, which helps mitigate the capital intensity of large Phase 3 trials.

Revenue recognized from collaborations fluctuates from quarter to quarter depending on the timing of milestones, cost reimbursements and accounting for performance obligations. In 2024, Arcus reported total revenue in the low hundreds of millions of US dollars, primarily related to the Gilead collaboration, while continuing to post a net loss driven by R&D expenses associated with its expanding clinical portfolio, according to the 2024 annual report published on 02/28/2025. This pattern is consistent with many companies at a similar stage of development in the biotech sector.

Operating expenses are largely composed of research and development spending, reflecting costs for clinical trials, manufacturing of investigational products, and preclinical research. General and administrative expenses remain a smaller but meaningful component. Arcus has indicated that R&D will continue to be the primary use of cash as it advances multiple Phase 2 and Phase 3 studies, although the exact spending trajectory will depend on trial enrollment, regulatory feedback and potential portfolio prioritization decisions discussed in earnings calls through 2025.

For US and international investors alike, the strength of the company’s balance sheet and the flexibility provided by its collaboration agreements are key when evaluating dilution risk from potential future equity raises. While additional financing cannot be ruled out in the biotech sector, the combination of existing cash and partnership funding increases Arcus’s ability to reach significant data readouts that could redefine its valuation profile.

Industry trends and competitive landscape in immuno-oncology

The broader immuno-oncology field remains highly competitive and scientifically dynamic. Over the past decade, PD-1 and PD-L1 checkpoint inhibitors have transformed the treatment of many tumors, particularly lung cancer and melanoma. However, a substantial proportion of patients either do not respond or eventually develop resistance, creating demand for new mechanisms of action and rational combinations that can overcome immune escape. Targets such as TIGIT, CD39 and the adenosine pathway fall into this category of next-wave immuno-oncology strategies.

Several large pharmaceutical and biotechnology companies are pursuing TIGIT-directed antibodies, some with Fc-effector function and others using Fc-silent designs similar to domvanalimab. The competitive field includes programs from players like Roche and Merck, among others, leading to a wide range of trial designs, cancer types and combination approaches. Results to date have been mixed, with some studies showing promising activity and others failing to meet primary endpoints, as reported in various press releases and oncology conference updates throughout 2022–2025.

In the CD39 and adenosine pathways, multiple agents are in early and mid-stage development across the industry. The central idea is to reduce adenosine-mediated immunosuppression in the tumor microenvironment, thereby enhancing T-cell and other immune cell activity. Arcus’s quemliclustat and small-molecule adenosine receptor antagonists compete with similar programs from other biopharma companies, yet differentiation may arise from biomarker strategies, tumor-type focus, and the specific combination partners selected. The success of this class will likely depend on refined patient selection and deeper understanding of resistance mechanisms.

These industry trends underscore both the opportunity and the risk for Arcus Biosciences. On one hand, strong clinical data from the company’s programs could be leveraged in a large and expanding oncology market, especially in the United States where new immunotherapies often see rapid uptake after approval. On the other hand, if competitor data prove more compelling or if regulators adopt stricter evidentiary standards following mixed experiences with the TIGIT class, Arcus may face challenges in achieving market differentiation.

Why Arcus Biosciences matters for US investors

Arcus Biosciences is listed on the New York Stock Exchange under the ticker RCUS, making it widely accessible to US retail and institutional investors via standard brokerage platforms. As a US-based biotech with a pipeline targeting large oncology indications, Arcus is directly exposed to reimbursement conditions, clinical practice patterns and regulatory decisions made in the United States, which collectively shape the commercial potential of new cancer medicines.

The partnership with Gilead adds another layer of relevance for US investors. Gilead is a major US biopharmaceutical company with established commercial infrastructure in oncology and other therapeutic areas. Positive data from Arcus’s programs could influence not only Arcus’s outlook but also strategic decisions at Gilead, including whether to expand co-commercialization efforts or pursue additional pipeline deals. These dynamics are often discussed in US equity research and news coverage around both companies, as reflected in banking and media reports published alongside earnings seasons in 2024 and 2025.

For investors interested in the broader immuno-oncology theme, Arcus provides exposure to differentiated mechanisms such as TIGIT and CD39 that are still in the clinical validation phase. The stock’s performance tends to be sensitive to major data presentations at US and global oncology conferences, including ASCO, ESMO and AACR, as well as to regulatory milestones like trial initiations, Phase 3 readouts and potential filing decisions. This event-driven profile is characteristic of many mid-cap US biotech names.

Conclusion

Arcus Biosciences occupies a prominent position among next-generation immuno-oncology developers, with domvanalimab and quemliclustat at the center of its value proposition. The collaboration with Gilead provides validation and financial support, yet success ultimately depends on the strength and consistency of clinical data emerging from Phase 2 and Phase 3 trials in lung and gastrointestinal cancers. The company’s cash resources and cost-sharing arrangements offer runway to pursue these pivotal studies, but like many clinical-stage US biotechs, Arcus faces the dual uncertainties of competitive dynamics and regulatory expectations. For market participants following US-listed oncology names, upcoming data readouts and partnership developments will likely continue to shape sentiment on Arcus Biosciences in the medium term.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.